Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin Extension Should Be Debated As Product-Specific Bill - Barr CEO

Executive Summary

The merits of a patent extension for Schering-Plough's Claritin should be debated in the context of a specific bill for that purpose, Barr CEO Bruce Downey contended at a House Judiciary/Courts & Intellectual Property Subcommittee hearing May 21.

You may also be interested in...

Claritin Carcinogenicity Data Central To Protracted Review - GAO

FDA revisited Claritin animal carcinogenicity data and its relevance to humans two and a half years into its review of the Schering-Plough antihistamine following an agency restructuring, the General Accounting Office said in an Aug. 10 report.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts